COST EFFECTIVENESS ANALYSIS OF THE USE OF DACLATASVIR plus ASUNAPREVIR IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN PERU

被引：0
|
作者：
Sanabria, C. [1 ]
Roman, R. [2 ]
Montano, D. [3 ]
Mercado, D. [3 ]
Valenzuela, G. [3 ]
Caporale, J. E. [4 ]
机构：
[1] Univ Nacl Mayor San Marcos, Lima, Peru
[2] EsSalud, Lima, Peru
[3] BMS, San Isidro, Peru
[4] BMS, Vicente Lopez, Argentina
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2910
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN25
引用
收藏
页码：A930 / A930
页数：1
相关论文
共 50 条
  • [41] Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naive Patients in Chile
    Vargas, Constanza L.
    Espinoza, Manuel A.
    Giglio, Andres
    Soza, Alejandro
    PLOS ONE, 2015, 10 (11):
  • [42] Randomized comparison of daclatasvir plus asunaprevir versus telaprevir plus peginterferon/ribavirin in Japanese hepatitis C virus patients
    Kumada, Hiromitsu
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Toyota, Joji
    Karino, Yoshiyasu
    Chayama, Kazuaki
    Kawakami, Yoshiiku
    Fujiyama, Shigetoshi
    Ito, Takayoshi
    Itoh, Yoshito
    Tamura, Etsuko
    Ueki, Tomoko
    Ishikawa, Hiroki
    Hu, Wenhua
    McPhee, Fiona
    Linaberry, Misti
    Hughes, Eric
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (01) : 14 - 22
  • [43] DACLATASVIR plus ASUNAPREVIR VERSUS SOFOSBUVIR/LEDIPASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN JAPANESE PATIENTS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Kelley, C.
    Ristovska, L.
    Signorovitch, J. E.
    Kalsekar, A.
    Wygant, G.
    McPhee, F.
    VALUE IN HEALTH, 2015, 18 (07) : A576 - A576
  • [44] ESTIMATING THE COST-EFFECTIVENESS OF DACLATASVIR REGIMENS FOR PATIENTS WITH ADVANCED CHRONIC HEPATITIS C IN THE UK
    McEwan, P.
    Webster, S.
    Ward, T.
    Kalsekar, A.
    Yuan, Y.
    Brenner, M.
    VALUE IN HEALTH, 2015, 18 (03) : A239 - A239
  • [45] COST EFFECTIVENESS OF DACLATASVIR/ASUNAPREVIR VERSUS PEGINTERFERON/RIBAVIRIN AND PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1B IN CHILE
    Vargas, C.
    Espinoza, M. A.
    Giglio, A.
    Soza, A.
    VALUE IN HEALTH, 2015, 18 (03) : A225 - A225
  • [46] Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
    Osawa, Mayu
    Ueno, Takayo
    Ishikawa, Hiroki
    Imai, Yasuhiko
    Garimella, Tushar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (11): : 1468 - 1478
  • [47] Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis
    Wang, Hui-Lian
    Lu, Xi
    Yang, Xudong
    Xu, Nan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (01) : 45 - 52
  • [48] Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
    Miyaki, Eisuke
    Imamura, Michio
    Hiraga, Nobuhiko
    Murakami, Eisuke
    Kawaoka, Tomokazu
    Tsuge, Masataka
    Hiramatsu, Akira
    Kawakami, Yoshiiku
    Aikata, Hiroshi
    Hayes, C. Nelson
    Chayama, Kazuaki
    HEPATOLOGY RESEARCH, 2016, 46 (08) : 758 - 764
  • [49] Daclatasvir plus asunaprevir in treatment-na?ve patients with hepatitis C virus genotype 1b infection
    Lai Wei
    Fu-Sheng Wang
    Ming-xiang Zhang
    Ji-dong Jia
    Alexey A Yakovlev
    Wen xie
    Eduard Burnevich
    Jun-qi Niu
    Yong Jin Jung
    xiang-Jun Jiang
    Min xu
    xin-Yue Chen
    qing xie
    Jun Li
    Jin-Lin Hou
    Hong Tang
    xiao-guang dou
    Yash gandhi
    Wen-Hua Hu
    Fiona McPhee
    Stephanie Noviello
    Michelle Treitel
    Ling Mo
    Jun deng
    World Journal of Gastroenterology, 2018, (12) : 1361 - 1372
  • [50] Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naive patients plus chronic hepatitis C
    Gimeno-Ballester, Vicente
    Mar, Javier
    San Miguel, Ramon
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 285 - 294
12345